688298 東方生物
按盤價 
31.900 +1.240 (+4.044%) | 2024/06 - 中期 人民幣(K¥) | 與去年同期 比較 | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | 2021/12 人民幣(K¥) | 2020/12 人民幣(K¥) | ||
| 營業總收入 | 418,235 | -16.61% | 820,157 | 8,767,938 | 10,169,168 | 3,265,356 | |
| 減：營業總成本 | 624,189 | 36.41% | 1,002,299 | 5,068,043 | 4,367,203 | 1,206,652 | |
| 其中:營業成本 | 269,301 | -16.80% | 467,403 | 4,314,399 | 2,665,325 | 677,778 | |
| 財務費用 | (71,640) | -68.49% | (275,581) | (603,272) | 67,239 | 57,790 | |
| 資產減值損失 | (9,025) | -0.40% | (236,509) | (1,209,740) | (16,671) | (75,467) | |
| 公允價值變動收益 | 15,460 | -1,763.22% | (8,990) | 1,660 | 44 | -- | |
| 投資收益 | 42,504 | 98.60% | 42,014 | 6,023 | 11,148 | 15,008 | |
| 其中：對聯營企業和合營企業的投資收益 | (1,542) | 235.75% | (1,498) | 1,914 | -- | -- | |
| 營業利潤 | (159,784) | -363.10% | (383,835) | 2,528,210 | 5,776,399 | 1,974,346 | |
| 利潤總額 | (157,450) | -365.89% | (404,227) | 2,470,752 | 5,769,966 | 1,974,281 | |
| 減：所得稅費用 | 2,594 | -87.80% | 14,042 | 373,321 | 829,320 | 293,950 | |
| 淨利潤 | (160,044) | -521.76% | (418,269) | 2,097,431 | 4,940,646 | 1,680,331 | |
| 減：非控股權益 | (8,437) | -368.79% | (20,685) | 29,717 | 20,458 | 2,972 | |
| 股東淨利潤 | (151,607) | -535.56% | (397,584) | 2,067,714 | 4,920,188 | 1,677,359 | |
市場價值指標 | |||||||
| 每股收益 (元) * | -0.760 | -547.06% | -1.970 | 12.310 | 41.000 | 14.280 | |
| 每股派息 (元) * | -- | -- | -- | 2.000 | 6.180 | 4.200 | |
| 每股淨資產 (元) * | 34.784 | -11.13% | 36.885 | 48.588 | 57.143 | 20.384 | |
| 審計意見 # | -- | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 即時報價更新時間為 18/10/2024 16:29 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
